Association between statin exposure and diabetes incidence among privately-insured patients before and after applying a novel technique to control for selection bias

Published:September 09, 2022DOI:



      The association between statins and incident diabetes mellitus (DM) in observational studies is much larger than that reported from randomized controlled trials. We sought to assess this association using a novel design controlling for selection bias.


      Using data from MarketScan, we identified a cohort of non-diabetic patients who initiated a statin and matched them to patients not taking statins. From the statin-user cohort, we identified two subgroups: patients who received statin refills for >6 months (continuers) and patients who received statin refills <6 months (discontinuers). Patients were followed for a minimum of two years to determine incident DM.


      We included 442,526 patients, divided equally between statin users and non-users. Statin use was associated with increased DM (9.9% vs. 4.4%, HR 2.2, p < 0.001). Among the 221,263 statin users, there were 194,357 continuers and 26,906 discontinuers. There was no significant difference in the incidence rate of DM between both groups (10.0% vs. 9.3%, HR 1.03, p = 0.22).


      Statin use was strongly associated with incident diabetes when users were compared to non-users but not when continuers were compared to discontinuers. Selection bias confounds the association between statin use and incident diabetes in observational studies.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to The American Journal of the Medical Sciences
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Baigent C
        • Blackwell L
        • et al.
        • Cholesterol Treatment Trialists’ (CTT) Collaboration
        Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials.
        Lancet. 2010; 376: 1670-1681
        • Mihaylova B
        • Emberson J
        • et al.
        • Cholesterol Treatment Trialists' (CTT) Collaborators
        The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials.
        Lancet. 2012; 380: 581-590
        • Taylor F
        • Huffman MD
        • Macedo AF
        • et al.
        Statins for the primary prevention of cardiovascular disease.
        Cochrane Database Syst Rev. 2013; CD004816
        • Ross SD
        • Allen IE
        • Connelly JE
        • et al.
        Clinical outcomes in statin treatment trials: a meta-analysis.
        Arch Internal Med. 1999; 159: 1793-1802
        • Koskinas KC
        • Siontis GCM
        • Piccolo R
        • et al.
        Effect of statins and non-statin LDL-lowering medications on cardiovascular outcomes in secondary prevention: a meta-analysis of randomized trials.
        Eur Heart J. 2017; 39: 1172-1180
        • Sattar N
        • Preiss D
        • Murray HM
        • et al.
        Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials.
        Lancet. 2010; 375: 735-742
        • Mansi I
        • Frei CR
        • Wang C-P
        • Mortensen EM.
        Statins and new-onset diabetes mellitus and diabetic complications: a retrospective cohort study of US healthy adults.
        J Gen Internal Med. 2015; 30: 1599-1610
        • Nakata M
        • Nagasaka S
        • Kusaka I
        • Matsuoka H
        • Ishibashi S
        • Yada T.
        Effects of statins on the adipocyte maturation and expression of glucose transporter 4 (SLC2A4): implications in glycaemic control.
        Diabetologia. 2006; 49: 1881-1892
        • Cederberg H
        • Stančáková A
        • Yaluri N
        • Modi S
        • Kuusisto J
        • Laakso M.
        Increased risk of diabetes with statin treatment is associated with impaired insulin sensitivity and insulin secretion: a 6 year follow-up study of the METSIM cohort.
        Diabetologia. 2015; 58: 1109-1117
        • Swerdlow DI
        • Preiss D
        • Kuchenbaecker KB
        • et al.
        HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials.
        Lancet. 2015; 385: 351-361
        • Sugiyama T
        • Tsugawa Y
        • Tseng C-H
        • Kobayashi Y
        • Shapiro MF.
        Is there gluttony in the time of statins? Different time trends of caloric and fat intake between statin-users and non-users among US adults.
        JAMA Internal Med. 2014; 174: 1038-1045
        • Culver AL
        • Ockene IS
        • Balasubramanian R
        • et al.
        Statin use and risk of diabetes mellitus in postmenopausal women in the women's health initiative.
        Arch Internal Med. 2012; 172: 144-152